Houot, Roch
Cartron, Guillaume
Bijou, Fontanet
de Guibert, Sophie
Salles, Gilles A. http://orcid.org/0000-0002-9541-8666
Fruchart, Christophe
Bouabdallah, Krimo
Maerevoet, Marie
Feugier, Pierre
Le Gouill, Steven
Tilly, Hervé
Casasnovas, Rene-Olivier
Moluçon-Chabrot, Cécile
Van Den Neste, Eric
Zachee, Pierre
Andre, Marc
Bonnet, Christophe
Haioun, Corinne
Van Hoof, Achiel
Van Eygen, Koen
Molina, Lysiane
Nicolas-Virelizier, Emmanuelle
Ruminy, Philippe
Morschhauser, Franck
Article History
Received: 6 July 2018
Revised: 28 August 2018
Accepted: 4 September 2018
First Online: 5 October 2018
Compliance with ethical standards
:
: RH: Honoraria: Bristol-Myers Squibb, Novartis, Janssen, Celgene, Consultant: Bristol-Myers Squibb; GC: Honoraria: Sanofi, Gilead, Janssen, Roche, Celgene, Consultant: Roche and Celgene; GS: Honoraria: Novartis Pharmaceuticals Corporation, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Gilead, Kite, Merck, Servier, Morphosys, Roche, Grants: Roche; KB: Honoraria: Takeda, Roche, Gilead, Advisory Board: Takeda, Roche; MM: Travel grants: Gilead, Roche, Abbvie, Advisory board: Abbvie, Takeda; PF: Honoraria: Gilead, Roche, Abbvie, Janssen, Consultant: Janssen, Gilead; SLG: Honoraria: Roche, Janssen, Celgene, Servier, Gilead, Advisory board: Roche, Janssen, Celgene, Research funding: Roche, Janssen, Celgene; HT: Honoraria: Celgene, Roche, Karyopharm, Astra-Zeneca, Bristol-Myers Squibb, Grants: Celgene; ROC: Honoraria: Celgene, Abbvie, Janssen, Consultant: Roche, Takeda, Merck, BMS, Research funding: Roche, Gilead; MA: Advisory Board: Celgene, Grants: Celgene, Roche; CB: Advisory board: Roche and Janssen; CA: Advisory Board: Roche, Celgene, Takeda, Janssen, Amgen, Kite/Gilead; ENV: Consultant: Janssen, Keocyt et Sanofi; FM: Advisory Board: Roche, Celgene, Janssen, BMS, Gilead, Consultant: Epizyme, Gilead. All the remaining authors declare that they have no conflict of interest.